Literature DB >> 7088281

Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment.

G Scotti, G Scialfa, S Pieralli, P G Chiodini, B Spelta, D Dallabonzana.   

Abstract

Thirty patients with macroprolactinomas were treated with dopaminergic drugs from a minimum of 4 months to a maximum of 6 years. Tumor size was evaluated with serial CT during treatment; serum prolactin levels and visual fields were also assessed at the same time. Reduction of PRL levels was found in 28 patients of whom 20 also had marked reduction of tumor volume on CT. Two patterns of reduction of size of tumor in relation with time were observed. In one, tumor shrinkage occurred rapidly in the first month and even in the first week after starting treatment. In the other pattern the tumor reduced in size only after some months of treatment. It is proposed that all patients with macroprolactinomas should be treated medically before considering surgery. A radiological diagnostic and research protocol is proposed, including scout views, thin slices, coronal sections, objective measurement of tumor size and density, serial CTs at 7,21,45 days, 6 months and then every year after the beginning of treatment.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7088281     DOI: 10.1007/BF00347554

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  8 in total

Review 1.  Evaluation of sellar and parasellar masses by computed tomography.

Authors:  T P Naidich; R S Pinto; M J Kushner; J P Lin; I I Kricheff; N E Leeds; N E Chase
Journal:  Radiology       Date:  1976-07       Impact factor: 11.105

2.  The use of coronal sections in evaluating lesions of the sellar and parasellar regions.

Authors:  N T Wolfman; M Boehnke
Journal:  J Comput Assist Tomogr       Date:  1978-07       Impact factor: 1.826

3.  Inhibitory effect of L-Dopa on GH release in acromegalic patients.

Authors:  A Liuzzi; P G Chiodini; L Botalla; G Cremascoli; F Silvestrini
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

4.  The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine).

Authors:  E Del Pozo; R B Del Re; L Varga; H Friesen
Journal:  J Clin Endocrinol Metab       Date:  1972-11       Impact factor: 5.958

5.  Lysenyl, a new antiserotonin agent. Pharmacological and clinical survey.

Authors:  I Podvalová; A Dlabac
Journal:  Res Clin Stud Headache       Date:  1970

6.  Attempt at pharmacological treatment of a pituitary tumor with bromocriptine.

Authors:  M Pawlikowski
Journal:  Endokrynol Pol       Date:  1978 Sep-Oct       Impact factor: 1.582

7.  Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas.

Authors:  T Eversmann; R Fahlbusch; H K Rjosk; K von Werder
Journal:  Acta Endocrinol (Copenh)       Date:  1979-11

8.  Computed tomography for diagnosis of empty sella associated with enhancing pituitary microadenoma.

Authors:  F Smaltino; F P Bernini; I Muras
Journal:  J Comput Assist Tomogr       Date:  1980-10       Impact factor: 1.826

  8 in total
  2 in total

1.  Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy.

Authors:  E Ciccarelli; S Grottoli; P Razzore; D Gaia; A Bertagna; S Cirillo; T Cammarota; M Camanni; F Camanni
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

2.  Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?

Authors:  Abdulrahman G Alkabbani; Sann Y Mon; Betul Hatipoglu; Laurence Kennedy; Charles Faiman; Robert J Weil; Amir H Hamrahian
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.